A multi-ethnic epigenome-wide association study of leukocyte DNA methylation and blood lipids
- PMID: 34183656
- PMCID: PMC8238961
- DOI: 10.1038/s41467-021-23899-y
A multi-ethnic epigenome-wide association study of leukocyte DNA methylation and blood lipids
Erratum in
-
Publisher Correction: A multi-ethnic epigenome-wide association study of leukocyte DNA methylation and blood lipids.Nat Commun. 2021 Jul 6;12(1):4256. doi: 10.1038/s41467-021-24600-z. Nat Commun. 2021. PMID: 34230475 Free PMC article. No abstract available.
Abstract
Here we examine the association between DNA methylation in circulating leukocytes and blood lipids in a multi-ethnic sample of 16,265 subjects. We identify 148, 35, and 4 novel associations among Europeans, African Americans, and Hispanics, respectively, and an additional 186 novel associations through a trans-ethnic meta-analysis. We observe a high concordance in the direction of effects across racial/ethnic groups, a high correlation of effect sizes between high-density lipoprotein and triglycerides, a modest overlap of associations with epigenome-wide association studies of other cardio-metabolic traits, and a largely non-overlap with lipid loci identified to date through genome-wide association studies. Thirty CpGs reached significance in at least 2 racial/ethnic groups including 7 that showed association with the expression of an annotated gene. CpGs annotated to CPT1A showed evidence of being influenced by triglycerides levels. DNA methylation levels of circulating leukocytes show robust and consistent association with blood lipid levels across multiple racial/ethnic groups.
Conflict of interest statement
Alan R Shuldiner is an employee of Regeneron Pharmaceuticals, Inc. Bruce M Psaty serves on the DSMB of a clinical trial funded by the manufacturer (Zoll LifeCor) and on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. Kim Valeska Emilie Braun works in ErasmusAGE, a center for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd.), Metagenics Inc. and AXA. All other authors declare no competing interests. The funders had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript.
Figures



References
-
- Lozano JV, et al. Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. Curr. Med Res Opin. 2008;24:659–670. - PubMed
-
- Petitti DB, et al. Serum lipids and glucose control: the SEARCH for Diabetes in Youth study. Arch. Pediatr. Adolesc. Med. 2007;161:159–165. - PubMed
-
- Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. J. Am. Soc. Nephrol. 2006;17:S145–S147. - PubMed
-
- Presecki P, et al. Serum lipid levels in patients with Alzheimer’s disease. Coll. Antropol. 2011;35:115–120. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- RC2 HL102419/HL/NHLBI NIH HHS/United States
- R01 HL104135/HL/NHLBI NIH HHS/United States
- R01 HL120393/HL/NHLBI NIH HHS/United States
- U01 HL130114/HL/NHLBI NIH HHS/United States
- HHSN268201100046C/HL/NHLBI NIH HHS/United States
- DH_/Department of Health/United Kingdom
- UL1 TR000124/TR/NCATS NIH HHS/United States
- U10 HL054457/HL/NHLBI NIH HHS/United States
- R01 HL133221/HL/NHLBI NIH HHS/United States
- R01 AG023629/AG/NIA NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- R01 HL103612/HL/NHLBI NIH HHS/United States
- HHSN268201100001I/HL/NHLBI NIH HHS/United States
- N01 HC085080/HL/NHLBI NIH HHS/United States
- R01 HL141292/HL/NHLBI NIH HHS/United States
- R01 ES020836/ES/NIEHS NIH HHS/United States
- U01 HL080295/HL/NHLBI NIH HHS/United States
- N01 HC085082/HL/NHLBI NIH HHS/United States
- HHSN268201100004I/HL/NHLBI NIH HHS/United States
- HHSN268200800007C/HL/NHLBI NIH HHS/United States
- N01 HC085086/HL/NHLBI NIH HHS/United States
- R01 NS087541/NS/NINDS NIH HHS/United States
- N01 HC085083/HL/NHLBI NIH HHS/United States
- P30 DK079626/DK/NIDDK NIH HHS/United States
- HHSN268201100003C/WH/WHI NIH HHS/United States
- R01 HL087652/HL/NHLBI NIH HHS/United States
- R01 HL119443/HL/NHLBI NIH HHS/United States
- R01 HL105756/HL/NHLBI NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- RC1 HL100185/HL/NHLBI NIH HHS/United States
- HHSN268201700002C/HL/NHLBI NIH HHS/United States
- HHSN268201200036C/HL/NHLBI NIH HHS/United States
- HHSN268201700001I/HL/NHLBI NIH HHS/United States
- N01 HC025195/HL/NHLBI NIH HHS/United States
- N01 HC055222/HL/NHLBI NIH HHS/United States
- U01 HL054457/HL/NHLBI NIH HHS/United States
- HHSN271201100004C/AG/NIA NIH HHS/United States
- HHSN268201700004I/HL/NHLBI NIH HHS/United States
- N01 HC085079/HL/NHLBI NIH HHS/United States
- BB/S020845/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- HHSN268201100002C/WH/WHI NIH HHS/United States
- 75N92021D00006/HL/NHLBI NIH HHS/United States
- HHSN268201700005C/HL/NHLBI NIH HHS/United States
- HHSN268201700001C/HL/NHLBI NIH HHS/United States
- HHSN268201700003C/HL/NHLBI NIH HHS/United States
- HHSN268201700004C/HL/NHLBI NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- HHSN268201100003I/HL/NHLBI NIH HHS/United States
- HHSN268201100002I/HL/NHLBI NIH HHS/United States
- HHSN268201300006C/HL/NHLBI NIH HHS/United States
- HHSN268201700002I/HL/NHLBI NIH HHS/United States
- HHSN268201700005I/HL/NHLBI NIH HHS/United States
- HHSN268201700003I/HL/NHLBI NIH HHS/United States
- MR/S019669/1/MRC_/Medical Research Council/United Kingdom
- HHSN268201100001C/WH/WHI NIH HHS/United States
- N01 HC085081/HL/NHLBI NIH HHS/United States
- R21 MD013296/MD/NIMHD NIH HHS/United States
- HHSN268201100004C/WH/WHI NIH HHS/United States
- R01 HL111089/HL/NHLBI NIH HHS/United States
- R01 HL116747/HL/NHLBI NIH HHS/United States
- R01 HL092111/HL/NHLBI NIH HHS/United States